Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

ABSTRACT:

Background

Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities.

Methods

In total, 125 oncology drugs were analyzed for positive germline pharmacogenomic associations in journals with impact factors ≥5. Studies were assessed for design and genotyping quality, clinically relevant outcomes, statistical rigor, and evidence of drug-gene effects. Associations from studies of high methodologic quality were deemed potentially clinically actionable, and translational summaries were written as point-of-care clinical decision support (CDS) tools and f

SUBMITTER: Wellmann R 

PROVIDER: S-EPMC6354920 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature